Company intelligence / Profile preview
JETEMA Co., Ltd.
- Ownership
- Private
- Employees
- ~227
- Development stage
- Commercial
Overview
JETEMA has commercialized several aesthetic medical products including hyaluronic acid fillers (e.p.t.q.®), PDO threads for lifting procedures, and a proprietary botulinum toxin type A ("THE TOXIN"). The company’s botulinum toxin product has completed or is undergoing Phase III clinical trials domestically. International approvals include CE marking for fillers and export licenses for toxins. Clinical studies have demonstrated long-term efficacy and safety of their new BoNT/A preparation in preclinical models[2][7].
- Therapeutic areas
- Dermatology
- Modalities
- Botulinum toxin (biologics/toxins)Hyaluronic acid fillers (medical devices/biomaterials)PDO threads (medical devices for lifting procedures)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on JETEMA Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JETEMA Co., Ltd..